Nexalin Launches NeuroCare, An AI Virtual Clinic for Brain Health Disorders
"NeuroCare will remove mental health stigma, eliminate access barriers, and lower costs"
Nexalin Technology unveiled NeuroCare on February 5, 2026, an AI-powered virtual clinic platform partnering with UC San Diego to deliver home-based neurostimulation therapy for Alzheimer's, mood disorders, TBI, and PTSD.
This subscription model integrates Nexalin's Gen-3 HALO headset with remote physician monitoring, obliterating clinic visit barriers while slashing costs and stigma.
The platform launches alongside UCSD clinical trials where patient enrollment now validates Gen-3 HALO's Deep Intracranial Frequency Stimulation (DIFS). NeuroCare enables private home treatment with real-time oversight, transitioning Nexalin from device sales to recurring subscription revenue capturing long-term patient data and adherence.
"NeuroCare removes mental health stigma, eliminates access barriers, lowers costs, building long-term client relationships with monthly subscriptions across Alzheimer's, mood disorders, and military care," said CEO Mark White. Stock surged 9-18% intraday on announcement.
How Does NeuroCare Help?
NeuroCare targets critical gaps in brain health delivery. Traditional psychiatric care demands office visits, medication stigma, and physician time.
NeuroCare delivers frequency-based DIFS therapy via HALO headset with AI monitoring, enabling physicians to manage multiple patients remotely. The Gen-3 system improves waveform penetration for deeper mid-brain stimulation without invasive procedures or side effects.
This builds momentum from Nexalin's clinical validation. October 2025 Radiology data confirmed Gen-2 DIFS enhanced Alzheimer's cognition and brain connectivity.
UCSD partnership accelerates Gen-3 adoption while generating proprietary outcomes data for subscription optimization. The model creates network effects. More patients improve AI monitoring, driving better adherence and results.
Subscription economics are compelling. One-time HALO sales evolve into monthly NeuroCare fees covering monitoring, physician time, and protocol adjustments. Patients gain privacy while physicians access real-time dashboards optimizing thousands simultaneously.
Execution is still a big challenge. First, clinical adoption. Gen-3 HALO succeeds in UCSD trials but subscription conversion demands proven superiority over TMS clinics and SSRIs.
Second, regulatory expansion. FDA clearance exists for prior generations, NeuroCare virtual oversight requires telehealth compliance across states. Third, payer reimbursement. Subscriptions must secure insurance coverage amid brain health's massive US market.
Nexalin challenges traditional neurology clinics, Big Pharma psych meds, and telepsychiatry scale players. Home-based DIFS trumps office TMS with superior penetration and zero surgery risks. NeuroCare authenticity proves patients value discretion over clinical environments.
Most digital therapeutics wait years for subscription flywheels. Nexalin launches with UCSD credibility and peer-reviewed momentum peers lack. Wall Street watches NXL's microcap volatility but the clinical-commercial bridge looks executable.
NeuroCare + HALO represents maximum asset value. DIFS positions brain health for subscription scale, balancing trials with revenue while capturing decade-long patient relationships.
Key Takeaways
- Nexalin launched NeuroCare, an AI-powered virtual clinic offering home-based neurostimulation therapy for brain health disorders.
- NeuroCare utilizes a subscription model integrating the Gen-3 HALO headset with remote physician monitoring, reducing stigma and costs.
- The platform aims to improve access to care for conditions like Alzheimer's, TBI, PTSD, and mood disorders via Deep Intracranial Frequency Stimulation.
- NeuroCare's launch transitions Nexalin from device sales to a recurring revenue model, enabling long-term patient data collection.